INVESTOR ALERT: Investigation of MoonLake Immunotherapeutics (MLTX) Announced by Holzer & Holzer, LLC

ATLANTA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQE: MLTX) complied with federal securities laws. On September 28, 2025, MoonLake reported results from its VELA-1 and VELA-2 Phase 3 program, disclosing that in “VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy.” Follo ...